ResApp Health Limited (ASX: RAP) is pleased to announce that it has won the Innovation Excellence Award, one of three main awards at the Tech23 2016 Awards Ceremony held last night in Sydney. Held annually for the past seven years, Tech23 is a national forum where Australian achievements are recognised and provides the ideal environment to help grow Australian innovation.
“It was an honour for the company to be recognised for its highly innovative smartphone-based technology for the diagnosis and management of respiratory disease,” said Tony Keating, CEO and Managing Director of ResApp. “I’d like to thank the entire ResApp team, and in particular, Associate Professor Udantha Abeyratne and his team at The University of Queensland.”
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.